Evidence map›Paper›PMID 32666679›Full record

ArticleChemical biology & drug design2021

Identification of potential modulators of osteosarcoma metastasis by high-throughput cellular screening of natural products.

Sarah A Long, Shan Huang, Anusha Kambala, Ling Ren, Jennifer Wilson, Michael Goetz, Xiaojiang Hao, Xiaosheng Yang, Ekaterina I Goncharova, Libin Jia and 4 more

Open access · greenAbstract read
In one paragraph

Article in Chemical biology & drug design, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Sarah A LongMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Shan HuangComparative Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Anusha KambalaComparative Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Ling RenComparative Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Jennifer WilsonMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Michael GoetzNatural Products Discovery Institute, Doylestown, PA, USA.
Xiaojiang HaoKey Laboratory of Chemistry for Natural Products in Guizhou Province, China Academy of Sciences, Gui Yang, China.
Xiaosheng YangKey Laboratory of Chemistry for Natural Products in Guizhou Province, China Academy of Sciences, Gui Yang, China.
Ekaterina I GoncharovaMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Libin JiaOffice of Cancer Complementary and Alternative Medicine, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA.
Amy LeBlancComparative Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Chand KhannaComparative Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Curtis J HenrichMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
John A BeutlerMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.ORCID 0000-0002-4646-1924
National Cancer Institute · USTarget (United States) · USKey Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences · CNDiscovery Institute · USLeidos (United States) · USNational Center for Complementary and Integrative Health · US

Funding

COP LaboratoryZIABC011692 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LEBLANC, AMY · 2016 to 2025
$15.5M
Building Libraries with Chemical Diversity for ScreeningZIABC011469 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BEUTLER, JOHN · 2012 to 2025
$7.8M
Development of Natural Product Leads as Anticancer TherapeuticsZIABC011470 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BEUTLER, JOHN · 2012 to 2025
$7.8M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA BC011469NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

A high-throughput screening assay was developed and applied to a large library of natural product extract samples, in order to identify compounds which preferentially inhibited the in vitro 2D growth of a highly metastatic osteosarcoma cell line (MG63.3) compared to a cognate parental cell line (MG63) with low metastatic potential. Evaluation of differentially active natural product extracts with bioassay-guided fractionation led to the identification of lovastatin (IC

Indexed as

Biological ProductsBone NeoplasmsCell LineCell MovementCell ProliferationCell SurvivalDrugs, Chinese HerbalHigh-Throughput Screening AssaysHumansLovastatinMeliaMonascusOsteosarcomaPlant ExtractsPyridinesSeedsBiological ProductscerivastatinDrugs, Chinese HerbalLovastatinPlant ExtractsPyridinestoosendaninTriterpeneshigh-throughput screeninglimonoidsmetastasisosteosarcomastatins

Identifiers

PMID32666679
PMCPMC8808376
OpenAlexW3043389453

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.